Roche has launched a high-throughput SARS-CoV-2 antigen test in markets, accepting the CE Mark to help in detecting Covid-19 infections.
The company has also sought emergency use authorisation (EUA) from the US Food and Drug Administration for the Elecsys SARS-CoV-2 Antigen test.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The highly accurate laboratory immunoassay is used for in vitro qualitative detection of the nucleocapsid antigen of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).
Data from clinical studies showed that the test had a 94.5% sensitivity across 200 PCR confirmed symptomatic persons and a 99.9% specificity across 2,747 PCR negative symptomatic and screening individuals.
The SARS-CoV-2 antigen test can be used as an alternative or along with PCR testing.
Roche Diagnostics CEO Thomas Schinecker said: “Healthcare systems remain under significant pressure to deliver robust testing options, with a sufficient number of tests available.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The launch of our high-throughput antigen test will provide additional testing capacity to reliably support healthcare systems in diagnosing SARS-CoV-2 infection, as a supplement to PCR testing.”
Performed by healthcare specialists, the test uses nasopharyngeal or oropharyngeal swab samples from patients with symptoms or those exposed to SARS-CoV-2.
The widely available assay could aid in cost and error reduction as it alleviates the need for manual handling and provides fast turn-around times and a high-test throughput.
The Elecsys SARS-CoV-2 Antigen immunoassay works on all Roche cobas e immunochemistry analysers available globally. It can deliver results in 18 minutes for a single test.
It has a throughput of up to 300 tests per hour from a single analyser. A positive result with the antigen test shows an active SARS-CoV-2 infection.
Roche intends to increase production plans to have a double-digit million number of tests per month by early next year across the world.
